Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | ATR | Q13535 | 9/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069994 | 0.86 | RET (0.35) | RETCYP4F2CYP4A11ATRF2R | |
| SCHEMBL5207821 | 0.82 | RET (0.39) | RETCYP4F2CYP4A11ATRF2R | |
| SCHEMBL6069803 | 0.81 | MAPK8 (0.36) | RETCYP4F2CYP4A11ATR | |
| SCHEMBL6070080 | 0.80 | KDM4E (0.38) | RETATRGAA | |
| SCHEMBL5211624 | 0.76 | CYP1A2 (0.34) | RETCYP4F2CYP4A11ATRF2R | |
| SCHEMBL30792181 | 0.72 | FGFR1 (0.34) | RETCYP4F2CYP4A11ATR | |
| SCHEMBL18198891 | 0.72 | FGFR1 (0.38) | RETCYP4F2CYP4A11ATRF2R | |
| SCHEMBL29705188 | 0.72 | FGFR1 (0.38) | RETCYP4F2CYP4A11ATRF2R | |
| SCHEMBL5205099 | 0.71 | KDR (0.38) | ATR | |
| SCHEMBL14527930 | 0.71 | MAP3K5 (0.34) | RETCYP4F2CYP4A11ATRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | RET 323/4885CYP4F2 4234/4885CYP4A11 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.